Hydromer, Inc. reported preliminary unaudited financial results for the first quarter of 2025, revealing a modest decline in both revenue and net income compared to the same period in 2024. The company's revenue decreased by 9% to $1.0 million, while net income dropped 64% to $112,000.
The financial performance was primarily attributed to legacy customer attrition and typical delays in onboarding new programs within the medical coatings industry. Despite these challenges, CEO Michael Torti emphasized the company's commitment to strategic investments aimed at long-term growth and market expansion.
Notably, Hydromer has decided to defer a comprehensive U.S. GAAP audit, citing resource constraints. The management team has instead focused on maintaining accurate internal financial records and improving operational efficiency.
The company continues to prioritize product development, customer partnerships, and technological innovation. With over four decades of experience in surface modification and coating solutions, Hydromer remains dedicated to building a scalable, innovation-driven platform across medical and industrial markets.
While the current financial results indicate short-term challenges, the company's strategic approach suggests a focus on future growth and market positioning in the competitive medical coatings sector.
